Inulanolide ACAS# 888941-86-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 888941-86-4 | SDF | Download SDF |
| PubChem ID | 102004674 | Appearance | Powder |
| Formula | C34H44O9 | M.Wt | 596.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC1CC2C(CC3=C(C4C(C13CC45C6C(CC(=C(C6O)C(C)CCCOC(=O)C)C)OC5=O)OC(=O)C)C)C(=C)C(=O)O2 | ||
| Standard InChIKey | FPZMKWNKHQRDMW-UNFPQQLUSA-N | ||
| Standard InChI | InChI=1S/C34H44O9/c1-15(9-8-10-40-20(6)35)26-16(2)11-25-28(29(26)37)34(32(39)43-25)14-33-17(3)12-24-22(18(4)31(38)42-24)13-23(33)19(5)27(34)30(33)41-21(7)36/h15,17,22,24-25,27-30,37H,4,8-14H2,1-3,5-7H3/t15-,17+,22-,24+,25?,27+,28?,29-,30?,33+,34+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Inulanolide A has potent cytotoxicity. 2. Inulanolide A is a novel NFAT1 and MDM2 dual targeting agent and may be a clinical candidate for breast cancer therapy. |
| Targets | Mdm2 | p53 |
Inulanolide A Dilution Calculator
Inulanolide A Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6759 mL | 8.3794 mL | 16.7588 mL | 33.5177 mL | 41.8971 mL |
| 5 mM | 0.3352 mL | 1.6759 mL | 3.3518 mL | 6.7035 mL | 8.3794 mL |
| 10 mM | 0.1676 mL | 0.8379 mL | 1.6759 mL | 3.3518 mL | 4.1897 mL |
| 50 mM | 0.0335 mL | 0.1676 mL | 0.3352 mL | 0.6704 mL | 0.8379 mL |
| 100 mM | 0.0168 mL | 0.0838 mL | 0.1676 mL | 0.3352 mL | 0.419 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fosinopril sodium
Catalog No.:BCC2141
CAS No.:88889-14-9
- Sprengerinin A
Catalog No.:BCN6658
CAS No.:88866-99-3
- Adrenorphin, Free Acid
Catalog No.:BCC1011
CAS No.:88866-92-6
- Sprengerinin C
Catalog No.:BCN6657
CAS No.:88861-91-0
- 11,12-De(methylenedioxy)danuphylline
Catalog No.:BCN4436
CAS No.:888482-17-5
- Ganetespib (STA-9090)
Catalog No.:BCC2336
CAS No.:888216-25-9
- Galanin (porcine)
Catalog No.:BCC5960
CAS No.:88813-36-9
- Gambogoic acid B
Catalog No.:BCN7936
CAS No.:887923-50-4
- Isogambogenic acid
Catalog No.:BCN3076
CAS No.:887923-47-9
- Gaudichaudic acid
Catalog No.:BCN3071
CAS No.:887923-46-8
- Bafetinib (INNO-406)
Catalog No.:BCC4036
CAS No.:887650-05-7
- (-)-Holostyligone
Catalog No.:BCN2863
CAS No.:887501-28-2
- Atrial natriuretic factor (1-28) (rat)
Catalog No.:BCC5843
CAS No.:88898-17-3
- Bafilomycin A1
Catalog No.:BCC3914
CAS No.:88899-55-2
- Mogroside V
Catalog No.:BCN1036
CAS No.:88901-36-4
- Mogroside IIIe
Catalog No.:BCN7924
CAS No.:88901-37-5
- Mogroside IIe
Catalog No.:BCN3168
CAS No.:88901-38-6
- Mogroside IVa
Catalog No.:BCN3165
CAS No.:88901-41-1
- Mogroside III-A1
Catalog No.:BCN3170
CAS No.:88901-42-2
- Mogroside III-A2
Catalog No.:BCN7925
CAS No.:88901-43-3
- Mogroside II-A1
Catalog No.:BCN7926
CAS No.:88901-44-4
- Mogroside II-A2
Catalog No.:BCN3180
CAS No.:88901-45-5
- (-)-Xestospongin C
Catalog No.:BCC7002
CAS No.:88903-69-9
- Mogroside IVe
Catalog No.:BCN3166
CAS No.:88915-64-4
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.[Pubmed:27105525]
Oncotarget. 2016 May 31;7(22):32566-78.
The transcription factor NFAT1 and the oncogene MDM2 have crucial roles in breast cancer development, progression, and metastasis. We have recently discovered that NFAT1 activates MDM2 expression. Here, we identified a small molecule (named Inulanolide A) that dually inhibited both NFAT1 and MDM2 in breast cancer cells in vitro and in vivo. Unlike conventional MDM2 inhibitors, Inulanolide A (InuA) exerted its selective anticancer activity in both p53-dependent and -independent manners. InuA decreased cell proliferation and induced G2/M phase arrest and apoptosis in breast cancer cells; it also led to a decrease in MDM2, NFAT1 and proteins associated with cell proliferation, and an increase in apoptotic signal related proteins. In a mouse orthotopic model, JapA suppressed tumor growth and lung metastasis without host toxicity. Thus, InuA is a novel NFAT1 and MDM2 dual targeting agent and may be a clinical candidate for breast cancer therapy. This study also validates the effectiveness of dually targeting NFAT1 and MDM2 in breast cancer.
Cytotoxic sesquiterpene lactone dimers isolated from Inula japonica.[Pubmed:25617784]
Fitoterapia. 2015 Mar;101:218-23.
Two new sesquiterpene lactone dimers, neojaponicone B (1) and inulanolide E (2) along with five known sesquiterpene lactone dimers (3-7, resp.) were isolated from the aerial parts of Inula japonica Thunb. The chemical structures of 1 and 2 were elucidated by detailed spectroscopic analysis. The relative configuration of 2 was confirmed by biomimetic transformation from the known sesquiterpene lactone dimer Inulanolide A (3). The cytotoxicities of the isolated sesquiterpene lactone dimers were evaluated against 6T-CEM and Jurkat cell lines. All compounds showed potent cytotoxicities with IC50 value of 2.2-5.9mum.
